Refer A Patient

Request An Appointment

Other

TREMFYA

TREMFYA (guselkumab) is the first medication of its kind to be approved by the Food and Drug Administration (FDA) in 2017.
Infusion or injection therapy referral
What it treats Plaque Psoriasis & Psoriatic Arthritis
Prescribed by Dermatologists & Rheumatologists
How it’s administered Intravenous (IV) infusion or subcutaneous injection
Frequency Single 100mg injection (Day 1), 1 injection 4 weeks later & 1 injection every 8 weeks
Length of treatment 8 weeks

About This Therapy

TREMFYA (guselkumab) is the first medication of its kind to be approved by the Food and Drug Administration (FDA) in 2017 to treat adults with moderate to severe plaque psoriasis. In July 2020, the FDA also approved TREMFYA to treat adults with active psoriatic arthritis.

For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.

TREMFYA REFERRAL FORM

TREMFYA REFERRAL FORM

Speak with your healthcare provider to learn if this therapy is right for you, then complete the referral form below.
REFERRAL FORM →

Ready to refer a patient for TREMFYA

Our team handles benefits verification, prior authorization, and scheduling so you can focus on care.